Skip to main content
Signal8

CDT Equity Inc. (CDT)

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

CDT Equity Inc. logo

CDT Equity Inc.

NASDAQ:CDTHealthcare
AH+5.56%$0.3800
Close$0.3600-4.51%
Mkt Cap$684K
EV-
Float1.76M
O/S1.9M
VOL316K sh
$ Vol$114K
RVOL0.13×
Inst Own0.0%
SI0.3%
Net Cash/Sh-
Dilution
CDT Equity Inc. logoNASDAQ:CDTAH$0.3800+5.56%

CDT Equity Inc. (CDT) dilution facts from SEC filings

Snapshot as of Sep 30, 2026, built from 51 SEC filings.

Shelf registration
S-3 filed Apr 22, 2026, effective May 1, 2026
Source: S-3 filed Apr 22, 2026
At-the-market (ATM) program
Yes, sales agreement dated Oct 23, 2024
Source: 10-Q filed Nov 16, 2026
Warrants outstanding
10 warrant series recorded as outstanding
Most recent offering
PIPE, closed Oct 6, 2026
Source: 8-K filed Oct 13, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro